上海康鹏科技股份有限公司 2024 年度 营业收入扣除情况专项审核报告 上海康鹏科技股份有限公司 2024 年度 营业收入扣除情况专项审核报告 众会字(2025)第 03606 号 上海康鹏科技股份有限公司全体股东: 我们接受委托，审计了上海康鹏科技股份有限公司（以下简称 "康鹏科技"）2024 年度的财务 报表，包括 2024 年 12 月 31 日的合并及公司资产负债表，2024 年度的合并及公司利润表、合并及公 司现金流量表、合并及公司股东权益变动表以及相关财务报表附注，并于 2025 年 4 月 16 日出具了众 会字(2025)第 03601 号审计报告。同时，我们审核了后附的康鹏科技 2024 年度营业收入扣除情况 表。 一、 管理层的责任 康鹏科技管理层的责任是提供真实、合法、完整的相关资料，按照《上海证券交易所科创板股票 上市规则》以及《科创板上市公司自律监管指南第 9 号——财务类退市指标：营业收入扣除》等要求 编制营业收入扣除情况表，并保证其内容真实、准确、完整，不存在虚假记录、误导性陈述或重大遗 漏。 二、 注册会计师的责任 我们的责任是对康鹏科技 2024 年度营业收入中是否存在与主营 ...

非经营性资金占用及其他关联资金往来情况 专项说明 上海康鹏科技股份有限公司 2024 年度 非经营性资金占用及其他关联资金往来情况 专项说明 上海康鹏科技股份有限公司 2024 年度 （此页无正文） 众会字(2025)第 03605 号 上海康鹏科技股份有限公司全体股东： 我们接受委托，依据《中国注册会计师执业准则》审计了上海康鹏科技股份有限公司(以下简称 "康鹏科技")2024 年度的财务报表，包括 2024 年 12 月 31 日的合并及公司资产负债表，2024 年度的合 并及公司利润表、合并及公司现金流量表、合并所有者权益变动表及公司所有者权益变动表以及财务 报表附注，并于 2025 年 4 月 16 日出具了众会字(2025)第 03601 号《审计报告》。 根据中国证券监督管理委员会《上市公司监管指引第 8 号——上市公司资金往来、对外担保的 监管要求》的要求以及参照上海证券交易所《上海证券交易所科创板上市公司自律监管指南第 7 号— —年度报告相关事项》规定的非经营性资金占用及其他关联资金往来情况汇总表格式，康鹏科技编制 了后附的 2024 年度非经营性资金占用及其他关联资金往来情况汇总表（以下简 ...

Financial Performance - The company's operating revenue for Q1 2025 was ¥243,177,446.14, representing a year-on-year increase of 44.27% compared to ¥168,553,569.90 in the same period last year[4] - The net profit attributable to shareholders of the listed company reached ¥30,629,054.29, a significant increase of 59.73% from ¥19,175,136.89 in the previous year[4] - Basic earnings per share increased by 50.00% to ¥0.06 from ¥0.04 in the previous year[5] - Operating profit for Q1 2025 was ¥35,530,317.84, compared to ¥21,117,251.23 in Q1 2024, reflecting a 68.3% increase[18] - Net profit for Q1 2025 was ¥30,474,142.75, up 56.7% from ¥19,441,477.03 in Q1 2024[19] Cash Flow - The net cash flow from operating activities was ¥103,812,462.17, a recovery from a negative cash flow of -¥20,741,294.03 in the same period last year[4] - Cash flow from operating activities for Q1 2025 was ¥103,812,462.17, a significant improvement from a negative cash flow of -¥20,741,294.03 in Q1 2024[21] - Cash inflow from investment activities in Q1 2025 totaled ¥472,442,856.15, compared to ¥204,112,893.57 in Q1 2024[21] - Cash outflow from investment activities in Q1 2025 was ¥718,095,973.86, down from ¥774,809,903.69 in Q1 2024[21] - The net increase in cash and cash equivalents was -166,171,630.29, compared to -563,221,202.58 in the previous period, showing an improvement of approximately 70%[22] - The ending balance of cash and cash equivalents was 555,056,796.67, up from 310,891,070.06 in the previous period, representing an increase of about 79%[22] Assets and Liabilities - The total assets at the end of the reporting period were ¥3,272,666,488.63, showing a slight increase of 0.54% from ¥3,255,092,762.50 at the end of the previous year[5] - The company's current assets totaled RMB 1,859,621,394.39, compared to RMB 1,821,509,888.98 in the previous period, reflecting a growth of approximately 2.09%[14] - The company's total liabilities were RMB 454,471,698.34, down from RMB 470,718,388.95, representing a decrease of approximately 3.5%[15] - The total non-current assets were RMB 1,413,045,094.24, slightly decreasing from RMB 1,433,582,873.52[14] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 9,513[10] - The largest shareholder, Ningbo Meishan Bonded Port Area Ou Chang Investment Management Co., Ltd., held 34.66% of the shares, totaling 180,006,984 shares[10] - Total equity attributable to shareholders reached ¥2,806,084,919.62 in Q1 2025, up from ¥2,772,109,591.34 in Q1 2024[16] Research and Development - Research and development expenses totaled ¥18,511,200.74, accounting for 7.61% of operating revenue, down from 11.11% in the previous year[5] Other Financial Metrics - The weighted average return on net assets increased to 1.10%, up from 0.68% in the previous year, reflecting improved profitability[5] - Non-recurring gains and losses amounted to ¥3,360,972.39, with government subsidies contributing ¥2,968,331.33 to this total[6] - Cash flow from financing activities totaled 35,412,893.19 in the current period, compared to 52,789,606.22 in the previous period, indicating a decrease of approximately 33%[22] - The company has not adopted new accounting standards or interpretations starting from 2025[22]

Financial Performance - The company reported a profit distribution plan for 2024, stating no profit distribution, no capital reserve transfer to share capital, and no bonus shares [5]. - The company faced a decline in operating revenue due to weak overall market performance and intense domestic competition, leading to a shift from profit to loss [3]. - The company's operating revenue for 2024 was CNY 674,813,318.15, a decrease of 31.11% compared to CNY 979,591,613.03 in 2023 [23]. - The net profit attributable to shareholders for 2024 was CNY -49,531,648.34, representing a decline of 143.95% from CNY 112,699,148.17 in 2023 [23]. - The cash flow from operating activities for 2024 decreased by 71.44% to CNY 60,797,379.56 from CNY 212,849,738.16 in 2023 [23]. - The basic earnings per share for 2024 was CNY -0.10, down 140.00% from CNY 0.25 in 2023 [25]. - The net profit excluding non-recurring gains and losses for 2024 was CNY -93,595,100.90, a decline of 216.62% from CNY 80,255,581.02 in 2023 [23]. - The company reported a total revenue of 1,370.88 million RMB for the current period, a decrease from 2,269.77 million RMB in the previous period [58]. Business Strategy and Adjustments - The company is actively adjusting its business strategy to mitigate risks from external and industry factors, aiming to return to a positive operational track [3]. - The company is shifting focus from small molecules to large molecules, particularly in the peptide raw material business, to create new growth points [38]. - The company emphasizes cost control and efficiency improvements as key strategies to navigate the competitive landscape [36]. - The company plans to lower product prices in 2024 to expand market share and diversify sales, particularly in the display materials segment [40]. - The establishment of a trading company in Singapore aims to mitigate geopolitical risks and enhance market presence [37]. - The company is focusing on reducing customer concentration to mitigate risks and enhance sales diversification [46]. Research and Development - The R&D expenditure as a percentage of operating revenue increased to 12.65% in 2024 from 8.87% in 2023, an increase of 3.78 percentage points [25]. - R&D investment totaled approximately ¥85.39 million, a slight decrease of 1.69% from the previous year, with R&D expenses accounting for 12.65% of revenue, an increase of 3.78 percentage points [56]. - The company holds a total of 115 patents, including 66 invention patents and 49 utility model patents, focusing on the fluorine chemical industry [39]. - The company is increasing its R&D efforts in OLED panel technology, establishing initial contacts with overseas clients [46]. Market Conditions and Competition - The overall market environment remains challenging, with increased competition and pressure on product pricing impacting revenue and profit margins [36]. - The company experienced a significant decline in revenue due to weak market performance and intense domestic competition, leading to pressure on product prices [26]. - The CDMO segment is experiencing significant variability in customer orders due to the pharmaceutical sales plans and geopolitical risks affecting the industry [40]. - The company is a leading domestic producer of LiFSI, with plans to enhance production efficiency despite current negative gross margins due to competitive pricing pressures [47]. Corporate Governance - The company has not proposed any special arrangements for corporate governance [8]. - The company maintains a sound corporate governance structure, complying with legal and regulatory requirements [134]. - There are no significant differences between the company's governance practices and the regulations set by the China Securities Regulatory Commission [134]. - The company has not reported any issues regarding independence from its controlling shareholders [134]. - The company is committed to protecting the legal rights of all shareholders and investors [134]. Environmental and Sustainability Efforts - The company has invested 31.5781 million yuan in environmental protection during the reporting period [187]. - The company received a CCC rating from Shanghai Huazheng Index Information Service Co., Ltd. in the ESG rating system [186]. - The company has established an ESG system that includes ESG management structure, risk management, and cultural construction to promote sustainable development [185]. - The company has implemented various pollution control measures, including waste gas treatment systems such as RTO and active carbon adsorption, ensuring compliance with emission standards [189]. - The company has taken measures to reduce carbon emissions during the reporting period [200]. Shareholder and Board Activities - The company held a total of 5 shareholder meetings during the reporting period, all in compliance with relevant laws and regulations [138]. - The board of directors held a total of 8 meetings during the year, with 2 in-person and 6 via communication methods [158]. - The company plans to present its 2023 annual financial results and budget for 2024 at the annual shareholders' meeting scheduled for May 21, 2024 [136]. - The company plans to implement a restricted stock incentive plan in 2024, as discussed in the compensation committee meetings [162]. Financial Risks and Challenges - The company faces risks related to high customer concentration, which could lead to significant performance fluctuations if major clients' purchasing behavior changes [67]. - There is a risk of continuous price decline for products due to weak overall market performance and intense domestic competition [67]. - The company is exposed to foreign exchange risks due to its export business, which could affect its operating performance if the RMB experiences significant fluctuations [68]. - The company is at risk of potential penalties and operational impacts due to stricter environmental protection regulations in the fine chemical industry [66].

上海康鹏科技股份有限公司 股东会议事规则 第二章 股东会的召集 第七条 董事会应在本规则第五条规定的期限内按时召集股东会。 第八条 经全体独立董事过半数同意，独立董事有权向董事会提议召开临时 股东会。对独立董事要求召开临时股东会的提议，董事会应当根据法律、行政法 规和《公司章程》的规定，在收到提议后 10 日内提出同意或不同意召开临时股 东会的书面反馈意见。 董事会不同意召开临时股东会，或者在收到提议后 10 日内未作出书面反馈 的，视为董事会不能履行或者不履行召集股东会会议职责，审计委员会可以自行 召集和主持。 第十条 单独或者合计持有公司 10%以上股份的股东有权向董事会请求召 开临时股东会，并应当以书面形式向董事会提出。 董事会应当根据法律、行政法规和《公司章程》的规定，在收到请求后 10 日内提出同意或不同意召开临时股东会的书面反馈意见。 董事会同意召开临时股东会的，应当在作出董事会决议后的 5 日内发出召开 股东会的通知，通知中对原请求的变更，应当征得相关股东的同意。董事会不同 意召开临时股东会，或者在收到请求后 10 日内未作出反馈的，单独或者合计持 有公司 10%以上股份的股东有权向审计委员会提 ...

上海康鹏科技股份有限公司 董事会议事规则 （九）法律、法规、《公司章程》或本规则规定的其他权利。 第四条 董事应当遵守法律、法规和《公司章程》的规定，应当采取措施避 免自身利益与公司利益冲突，不得利用职权牟取不正当利益，对公司负有下列忠 实义务： （一）不得侵占公司的财产、不得挪用公司资金； （二）不得将公司资产或者资金以其个人名义或者其他个人名义开立账户存 储； （三）不得利用职权贿赂或者收受其他非法收入； （四）未向董事会或者股东会报告，并按照《公司章程》的规定经董事会或 者股东会决议通过，不得直接或者间接与本公司订立合同或者进行交易； （五）不得利用职务便利，为自己或他人谋取属于公司的商业机会，但向董 事会或者股东会报告并经股东会决议通过，或者公司根据法律、行政法规或者《公 司章程》的规定，不能利用该商业机会的除外； （六）未向董事会或者股东会报告，并经股东会决议通过，不得自营或者为 他人经营与本公司同类的业务； （七）不得接受他人与公司交易的佣金归为己有； （八）不得擅自披露公司秘密； （九）不得利用其关联关系损害公司利益； （十）法律、行政法规、部门规章及本章程规定的其他忠实义务。 董事违反本条规定 ...

证券代码：688602 证券简称：康鹏科技 公告编号：2025-027 上海康鹏科技股份有限公司 关于修订《公司章程》、 相关议事制度及部分管理制度的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海康鹏科技股份有限公司（以下简称"公司"）于 2025 年 4 月 16 日召开 第三届董事会第三次会议，审议通过《关于修订<公司章程>、相关议事制度及部 分管理制度的议案》，该议案尚需提交股东大会审议。现将相关情况公告如下： 一、公司经营范围增加的情况 根据公司经营发展需要和实际情况，结合公司战略发展规划，拟将"货物进 出口、技术进出口"增加至公司的经营范围。 原经营范围：经公司登记机关核准，公司经营范围为：电子、材料、生物、 医药（以上除基因生物、人体干细胞和基因诊断与治疗）领域内的技术研究开发 以及相关原料、中间体和产品的生产、加工、销售（不涉及国营贸易管理商品， 涉及配额、许可证管理商品的，按国家有关规定办理），自有技术的转让，提供 相关的技术咨询和技术服务（以上均除危险、易制毒、监控类专项化学品）。【依 法须经 ...

上海康鹏科技股份有限公司 其他材料进行认真审核，出现不清楚或不理解的情形，也会及时向公司管理层进 行咨询了解，以便在会议上明确、客观地发表意见，独立、审慎地行使各项表决 权，对相关事项发表独立意见；对董事会审议的各项议案均投了赞成票，未对公 司任何事项提出异议。 (一) 本年度出席董事会、股东大会和专门委员会情况 2024 年度独立董事述职报告 本人作为上海康鹏科技股份有限公司（以下简称"公司"）的独立董事，2024 年严格按照《中华人民共和国公司法》《中华人民共和国证券法》《上海证券交 易所科创板股票上市规则》《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》《上市公司独立董事管理办法》等法律法规、规范性文件以及 《上海康鹏科技股份有限公司章程》（以下简称"《公司章程》"）等内部制度 的规定，本着对全体股东负责的态度，认真审慎地行使公司和股东大会赋予的权 力，及时关注公司经营情况，积极出席公司股东大会、董事会及各专门委员会会 议，对公司董事会审议的相关重大事项发表公正、客观的独立意见，为董事会的 科学决策提供支撑，促进公司可持续发展，维护公司和全体股东特别是中小股东 的合法权益。现就 202 ...